According to FutureWise analysis the Humanized Liver Mice Model Market in 2025 is US$ 130.2 million, and is expected to reach US$ 271.9 million by 2033 at a CAGR of 9.64%. Market growth is driven by the rising demand for reliable preclinical models in drug metabolism, hepatotoxicity studies, and research on infectious diseases like hepatitis and liver fibrosis. Humanized liver mice provide better translational relevance than traditional models, accelerating drug discovery and reducing clinical trial failures.
To improve the understanding of mammalian and human genome function and have effective therapies designed, humanized liver mice market plays a vital role. The rising need for development and efficient research and useful results, the global market for humanized liver mice is growing. High expenses and technical requirements may restrict the market.
Rapid modernisation which promotes the genetic engineering of mouse genomes such as the development of knock-out mouse, knock-in mouse as well as the transgenic mouse has led to lucrative trade. To encourage the robust genetic modification of mice, advancements in technology are rapid, which promotes the engineering of new immune-deficient mice models for capitalizing on the discovery of novel approaches to enhance the engraftment of human cells or tissues. Engrafting the mouse liver with human hepatocytes and mouse bone marrow with human hematopoietic stem cells is a great discovery, expected to propel the market.
Advancements in Genetic Engineering: Techniques such as CRISPR-Cas9 have allowed for more precise modifications to mouse genomes, thereby enhancing the relevance of liver models in human disease research.